Gamifant (emapalumab-lzsg) Coverage
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0077L alerts
Get alerted when Policy 2026D0077L changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization requirements for Gamifant administered for primary hemophagocytic lymphohistiocytosis (HLH) or HLH/macrophage activation syndrome (MAS) associated with Still's disease for UnitedHealthcare Commercial and Individual Exchange benefit plans.
The policy was transferred to a shared template applicable to UnitedHealthcare Commercial and Individual Exchange benefit plans.
The policy added an Application section identifying UnitedHealthcare Commercial and Individual Exchange benefit plans.
The Clinical Evidence and References sections were updated to reflect current information.
Previous policy versions 2026D0077K and IEXD0077 were archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.